Corgard Side Effects
Generic name: nadolol
Note: This document contains side effect information about nadolol. Some of the dosage forms listed on this page may not apply to the brand name Corgard.
Some side effects of Corgard may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to nadolol: oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking nadolol (the active ingredient contained in Corgard) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
slow or uneven heartbeats;
numbness or cold feeling;
feeling like you might pass out;
feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
bronchospasm (wheezing, chest tightness, trouble breathing);
hallucinations, behavior changes; or
nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Less serious side effects of nadolol may include:
dizziness, spinning sensation;
mild nausea, diarrhea, constipation, upset stomach, bloating, gas; or
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to nadolol: compounding powder, oral tablet
Rare cases of A-V heart block are reported.
Cardiovascular side effects are usually mild and transient and rarely require discontinuation of therapy. Bradycardia, hypotension, conduction disturbances, chest pain, and heart failure have each been reported in 1% to 3% of patients. Complaints of cold extremities have been reported in approximately 5% of patients. Edema has rarely been associated with the use of nadolol.
Nadolol is hydrophilic and is less likely to penetrate into the central nervous system compared to other beta-blockers. Depression and anxiety are reported in one patient while receiving nadolol (the active ingredient contained in Corgard) The symptoms started two days after an increase in his dosage and resolved within three days of discontinuing nadolol. Organic brain syndrome was diagnosed in two patients receiving nadolol should be considered as a possible cause of acute deterioration in mental or emotional status.
The most common nervous system side effect appears to be fatigue (up to 10% of patients). Headache or dizziness have been reported in 5% and 8% of patients, respectively.
At least one case of severe bronchospasm associated with nadolol (the active ingredient contained in Corgard) therapy is reported. This patient had a history of childhood asthma and exercise-induced bronchospasm requiring albuterol inhalations. After one dosage of nadolol the patient had a respiratory arrest and required mechanical ventilation for several days. If nadolol is necessary in a patient with a history of bronchospasm, it is recommended that therapy be initiated in a controlled environment with bronchodilators available.
Respiratory system side effects have been rare (1 in 1,000), but may be important in patients with reactive airways disease. The use of nadolol has been associated with precipitation of bronchospasm in patients with a history of asthma.
Gastrointestinal problems, such as nausea, diarrhea, constipation, and general abdominal upset have each been reported in less than 1% of patients.
Psychiatric side effects have been limited to anxiety-depression in approximately 4% of patients.
Renal insufficiency has not associated with nadolol (the active ingredient contained in Corgard) but one study of 10 elderly hypertensive patients has shown that the antihypertensive effect of nadolol was associated with a decrease in effective renal blood flow. The glomerular filtration rate in affected patients remained stable, however.
Hematologic side effects have included at least one reported case of nadolol-associated thrombocytopenia.
More Corgard resources
- Corgard Prescribing Information (FDA)
- Corgard MedFacts Consumer Leaflet (Wolters Kluwer)
- Corgard Concise Consumer Information (Cerner Multum)
- Corgard Advanced Consumer (Micromedex) - Includes Dosage Information
- Corgard Monograph (AHFS DI)
- Nadolol Prescribing Information (FDA)
- Nadolol Professional Patient Advice (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.